540788
ASPIRA
Start SIP
Invest Now
Start SIP in ASPIRA
Performance
- Low
- ₹68
- High
- ₹68
- 52 Week Low
- ₹50
- 52 Week High
- ₹107
- Open Price₹68
- Previous Close₹68
- Volume951
- 50 DMA₹64.55
- 100 DMA₹64.22
- 200 DMA₹63.06
Investment Returns
- Over 1 Month + 9.38%
- Over 3 Month + 11.13%
- Over 6 Month + 8.45%
- Over 1 Year -0.98%
Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!
Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 20.6
- PEG Ratio
- 0
- Market Cap Cr
- 70
- P/B Ratio
- 4.9
- Average True Range
- 3.63
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- -0.18
- RSI
- 56.51
- MFI
- 72.37
Aspira Pathlab & Diagnostics Financials
Aspira Pathlab & Diagnostics Technicals
EMA & SMA
Current Price
₹68.00
+
0.01
(0.01%)
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹64.65
- 50 Day
- ₹64.55
- 100 Day
- ₹64.22
- 200 Day
- ₹63.06
Resistance and Support
68
- R3 68.01
- R2 68.01
- R1 68.00
- S1 67.99
- S2 67.99
- S3 67.98
Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-10 | Quarterly Results | |
| 2025-11-12 | Quarterly Results | |
| 2025-08-12 | Quarterly Results | |
| 2025-05-16 | Audited Results | |
| 2025-02-07 | Quarterly Results |
Aspira Pathlab & Diagnostics F&O
About Aspira Pathlab & Diagnostics
- NSE Symbol
- ASPIRA
- BSE Symbol
- 540788
- Managing Director & CEO
- Dr. Pankaj J Shah
- ISIN
- INE500C01017
Similar Stocks to Aspira Pathlab & Diagnostics
Aspira Pathlab & Diagnostics FAQs
Aspira Pathlab & Diagnostics share price is ₹68 As on 10 February, 2026 | 22:47
The Market Cap of Aspira Pathlab & Diagnostics is ₹70 Cr As on 10 February, 2026 | 22:47
The P/E ratio of Aspira Pathlab & Diagnostics is 20.6 As on 10 February, 2026 | 22:47
The PB ratio of Aspira Pathlab & Diagnostics is 4.9 As on 10 February, 2026 | 22:47
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.